GCNT7

Across TCGA pan-cancer cohorts, GCNT7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GCNT7 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GCNT7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GCNT7 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and GBM are the cancer types where GCNT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.216	0.845	.024	9	view →
CCRCC	DFS	Median	IV	0.150	1.000	.024	9	view →
GBM	DFS	Tertile	All	0.632	0.958	.020	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GCNT7–PDAC (DFS)

Open the PDAC breakdown →